C4 Therapeutics sets cemsidomide trial timelines through 2028
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- Wall St indexes climb as US, Iran halt attacks; Comcast surges on spin-off plan
- Tech funds suffer record outflows as investors trim equity positions
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- Needham Starts NeoVolta (NEOV) at Buy
- Personalis, Inc. (PSNL) and Tempus (TEM) Expand Collaboration
- Strategy stock jumps 7% as firm shifts to active capital management
- US allows Anthropic to release Mythos AI to 'trusted' US organizations
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways
January 14, 2026 7:00 AM EST Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µg
Cemsidomide Phase 1b Trial in Combination With Elranatamab On Track to Initiate in Q2 2026
Internal Discovery Strategy Progressing Efforts Focused on Inflammation, Neuro-inflammation and Neuro-degenerative Diseases With Novel Targets in Clinically Validated Pathways
Cash Runway to End of 2028 Provides Funding Through Key Value Inflection Points
WATERTOWN, Mass., Jan. 14, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein... More
